TG Therapeutics (NASDAQ: TGTX) reported Q1 EPS of $0.03, $0.13 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $119.7 million versus the consensus estimate of $117.13 million.

GUIDANCE:

TG Therapeutics sees FY2025 revenue of $575 million, versus the consensus of $553 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.